Literature DB >> 22956510

Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease.

Laura L Kilarski1, Justin P Pearson, Victoria Newsway, Elisa Majounie, M Duleeka W Knipe, Anjum Misbahuddin, Patrick F Chinnery, David J Burn, Carl E Clarke, Marie-Helene Marion, Alistair J Lewthwaite, David J Nicholl, Nicholas W Wood, Karen E Morrison, Caroline H Williams-Gray, Jonathan R Evans, Stephen J Sawcer, Roger A Barker, Mirdhu M Wickremaratchi, Yoav Ben-Shlomo, Nigel M Williams, Huw R Morris.   

Abstract

Approximately 3.6% of patients with Parkinson's disease develop symptoms before age 45. Early-onset Parkinson's disease (EOPD) patients have a higher familial recurrence risk than late-onset patients, and 3 main recessive EOPD genes have been described. We aimed to establish the prevalence of mutations in these genes in a UK cohort and in previous studies. We screened 136 EOPD probands from a high-ascertainment regional and community-based prevalence study for pathogenic mutations in PARK2 (parkin), PINK1, PARK7 (DJ-1), and exon 41 of LRRK2. We also carried out a systematic review, calculating the proportion of cases with pathogenic mutations in previously reported studies. We identified 5 patients with pathogenic PARK2, 1 patient with PINK1, and 1 with LRRK2 mutations. The rate of mutations overall was 5.1%. Mutations were more common in patients with age at onset (AAO) < 40 (9.5%), an affected first-degree relative (6.9%), an affected sibling (28.6%), or parental consanguinity (50%). In our study EOPD mutation carriers were more likely to present with rigidity and dystonia, and 6 of 7 mutation carriers had lower limb symptoms at onset. Our systematic review included information from >5800 unique cases. Overall, the weighted mean proportion of cases with PARK2 (parkin), PINK1, and PARK7 (DJ-1) mutations was 8.6%, 3.7%, and 0.4%, respectively. PINK1 mutations were more common in Asian subjects. The overall frequency of mutations in known EOPD genes was lower than previously estimated. Our study shows an increased likelihood of mutations in patients with lower AAO, family history, or parental consanguinity.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22956510     DOI: 10.1002/mds.25132

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  43 in total

1.  PARK2 attenuates house dust mite-induced inflammatory reaction, pyroptosis and barrier dysfunction in BEAS-2B cells by ubiquitinating NLRP3.

Authors:  Xiahui Ge; Feng Cai; Yan Shang; Feng Chi; Hua Xiao; Jing Xu; Youhui Fu; Chong Bai
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

2.  Foot Drop Dystonia Resulting from parkin (PARK2) Mutation.

Authors:  Laura J de Schipper; Agnita J W Boon; Alexander G Munts
Journal:  Mov Disord Clin Pract       Date:  2015-06-04

3.  The MTHFR C677T polymorphism modifies age at onset in Parkinson's disease.

Authors:  Annamaria Vallelunga; Valentina Pegoraro; Manuela Pilleri; Roberta Biundo; Angela De Iuliis; Mauro Marchetti; Silvia Facchini; Patrizia Formento Dojot; Angelo Antonini
Journal:  Neurol Sci       Date:  2013-09-20       Impact factor: 3.307

Review 4.  The role of monogenic genes in idiopathic Parkinson's disease.

Authors:  Xylena Reed; Sara Bandrés-Ciga; Cornelis Blauwendraat; Mark R Cookson
Journal:  Neurobiol Dis       Date:  2018-11-15       Impact factor: 5.996

Review 5.  Parkinsonism and inborn errors of metabolism.

Authors:  A Garcia-Cazorla; S T Duarte
Journal:  J Inherit Metab Dis       Date:  2014-06-07       Impact factor: 4.982

6.  hVMAT2: A Target of Individualized Medication for Parkinson's Disease.

Authors:  Nian Xiong; Nuomin Li; Eden Martin; Jinlong Yu; Jie Li; Jing Liu; David Yue-Wei Lee; Ole Isacson; Jeffery Vance; Hong Qing; Tao Wang; Zhicheng Lin
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

7.  Early-onset Parkinson's disease due to PINK1 p.Q456X mutation--clinical and functional study.

Authors:  Joanna Siuda; Barbara Jasinska-Myga; Magdalena Boczarska-Jedynak; Grzegorz Opala; Fabienne C Fiesel; Elisabeth L Moussaud-Lamodière; Leslie A Scarffe; Valina L Dawson; Owen A Ross; Wolfdieter Springer; Ted M Dawson; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2014-09-02       Impact factor: 4.891

8.  Genetic risk and age in Parkinson's disease: Continuum not stratum.

Authors:  Mike A Nalls; Valentina Escott-Price; Nigel M Williams; Steven Lubbe; Margaux F Keller; Huw R Morris; Andrew B Singleton
Journal:  Mov Disord       Date:  2015-03-17       Impact factor: 10.338

Review 9.  Recent advances in Parkinson’s disease genetics.

Authors:  Steven Lubbe; Huw R Morris
Journal:  J Neurol       Date:  2014-02       Impact factor: 4.849

Review 10.  Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson's Disease: A Meta-Analysis.

Authors:  Dan Xie; Ling Feng; Hongyan Huang; Quanzhen Zhao; Pingping Ning; Qiuyan Shen; Haitao Lu; Fang Xu; Yanming Xu
Journal:  Behav Neurol       Date:  2021-05-31       Impact factor: 3.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.